ImmunoCellular Therapeutics Announces Licensing Agreement with University of Pennsylvania for Enhanced Dendritic-Cell Production Technology

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (OTCBB: IMUC) today announced that it has entered into an agreement with the University of Pennsylvania under which University of Pennsylvania has granted the Company an exclusive, worldwide license for a patent pending technology for the production of high-activity dendritic cells (DCs). The license covers the application of this technology to the development of therapeutics for all indications except breast cancer and ductal carcinoma i

Feed Date: 
February 21, 2012